Latus Bio Appointed New Board Members
The Philadelphia-based biotech firm added two experienced executives to help oversee its transition to clinical-stage work.
Updated on Sept. 19, 2026 in Biotech
Live Poll
Do you trust biotechnology companies to effectively develop and bring new gene therapies to patients?
Latus Bio has appointed Donald Hayden as chairman of the board and Michael MacLean as an independent director. These appointments come as the Philadelphia company prepares to advance its gene therapies for CLN2 and Huntington's disease into clinical trials.
Why it matters
These additions provide Latus Bio with critical experience in pharmaceutical operations and financing as the company pivots to clinical-stage development. The leadership expansion supports the advancement of its gene therapies, which utilize AAV capsid variants for low-dose delivery.
Latus Bio is leveraging AAV capsid variants to enable low-dose gene therapy delivery. The company is currently developing LTS-101 for CLN2 disease and LTS-201 for Huntington's disease.
The players
Donald Hayden
He is the new board chairman at Latus Bio who previously spent 25 years at Bristol Myers Squibb.
Michael MacLean
He is an independent director at Latus Bio and the former chief financial officer of Avidity Biosciences.
Latus Bio
This Philadelphia-based company is a developer of gene therapies focused on CLN2 and Huntington's disease.
The details
Donald Hayden brings 40 years of experience to the role, including 25 years at Bristol Myers Squibb where he served as president of Global Pharmaceuticals. Michael MacLean joins the board after serving as the CFO of Avidity Biosciences, which was acquired by Novartis for over $12 billion in 2026.
Timeline
2008: Donald Hayden began his tenure as board chair for Otsuka America Pharmaceutical.
2025: Eli Lilly completed its acquisition of Verve Therapeutics.
2026: Novartis acquired Avidity Biosciences for over $12 billion.
September 19, 2026: The appointments of Hayden and MacLean were announced.
The Tech Race
The firm's move mirrors a broader industry trend where emerging biotechs recruit leaders with track records in high-value exits to navigate the transition from research to clinical development. This signals Latus Bio's ambition to compete in the specialized gene therapy market alongside established players.
For investors and biotech observers, this leadership shift indicates a concrete move toward the clinical testing phase of Latus Bio's therapeutic pipeline. The new board oversight may influence the company's speed in reaching regulatory milestones and its long-term market strategy.
The takeaway
Expanding a board with experienced pharmaceutical executives is a standard signal that a company is preparing for the complexities of clinical-stage operations. Readers should monitor future press releases for official dates on upcoming phase trials.
Further reading
For more developments in the local sector, visit the Philadelphia biotech section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust biotechnology companies to effectively develop and bring new gene therapies to patients?
